Half-Year Report Sartorius: High order intake and sales – share makes a leap upwards

Created: 07/21/2022, 21:33

By: Thomas Copytz

The Göttingen Dax group Sartorius presents its half-year results.

High incoming orders and sales confirm the top forecast for the year.

Goettingen – The life science group Sartorius AG from Goettingen has once again presented strong figures: In the first half of 2022, sales and earnings increased by double digits, sales adjusted for exchange rate effects by 20.9 percent to 2.06 billion euros, the operating result EBITDA by 25, 6 percent to 697 million euros.

The relevant consolidated net profit was 334 million euros, which is 28.6 percent more than in the first half of 2021. The price of the share reacted promptly, after the stock exchange opened on Thursday (July 21, 2022) at 11 a.m. a set of 366 opened 393 euros, as reported by hna.de.

Sartorius presents half-year results: High order intake and sales

Will be further expanded: Additional production buildings are currently being built on the Sartorius AG campus in the Goettingen industrial area.

The group presented strong half-year figures for 2022 and hired another 2,000 employees.

© Hubert Jelinek

“Sartorius performed well in a challenging environment in the first half of the year.

It was a good first half of the year," summarized CEO Dr.

Joachim Kreuzburg together in a press conference on Thursday morning.

Sartorius performed well in a challenging environment in the first half of the year.

It was a good first half of the year.

dr

Joachim Kreuzburg, CEO of Sartorius

The main driver of the strong development is a good order situation with a volume of 2.17 billion euros and organic growth in both the laboratory and bioprocess divisions, while acquisitions, i.e. purchases of companies - there were two in the first half of the year - almost 2 percentage points contributed to the increase in sales.

Also positive: Growth was double-digit percentages in all three business regions – Greater Europe, Americas and Asia/Pacific.

The pandemic-related restrictions in China had a "relatively small impact on growth".

Nor were there any negative currency effects.

Göttingen Dax group Sartorius: the share makes a leap upwards

This means that Sartorius AG, which is listed in the Dax, is still on course for the targeted annual business figures.

Kreuzburg confirmed the outlook for 2022 given a year ago with an increase in sales of 15 to 19 percent and an EBITDA margin of around 34 percent.

However, he did not want to limit this forecast, especially in terms of sales.

also read

Thousands of indigenous children abused: Will the Pope in Canada make amends?

Tom and Bill Kaulitz: Are the Tokio Hotel brothers buying a prison in Lower Saxony?

On the other hand, from his point of view, the continuing major uncertainties - based on the critical political and economic world situation, the energy supply and general material availability and supply chain problems speak.

Sartorius is affected by this, albeit by no means as severely as other industries, outlined Kreuzburg, who praised his "teams" who had done a great deal worldwide to keep the supply chains running.

Life science group Sartorius: Top annual forecast for 2022 remains in place

The energy supply is also an uncertainty factor.

According to Kreuzburg, Sartorius also tried early on to achieve greater independence from natural gas there – the Göttingen campus has dual burners that can be operated with gas and oil.

This also generates steam, which is sometimes necessary for production.

The expansion with gas/oil burners was still relatively cheap, "because we were early," said Joachim Kreuzburg, who also mentioned a minus point, albeit a marginal one.

Sartorius CEO: Dr.

Joachim Kreuzberg.

© Sartorius/nH

Incoming orders have “normalized”, especially in the stronger Bioprocess Solutions division, as Kreuzburg said.

Reason: In the comparative period of 2021, some Sartorius customers ordered more than what was needed - also due to the corona vaccine production.

A normalization was to be expected.

The number of employees at Sartorius AG rises to 15,795 – around 2,000 new jobs since the beginning of the year

Joachim Kreuzburg always mentions the development of the number of employees in the press conferences – not without pride: After 4,000 new employees in the previous year, Sartorius created a good 2,000 new jobs in the first half of the year, and now states the total number at 15,795.

"We continue to have a very solid balance sheet and financial position," summarizes Kreuzburg - also with a view to the equity ratio of a good five percent of 35.9 percent.

A value that analysts at Sartorius have been quick to criticize in recent years.

(tko)

As early as April 2022, the Lower Saxony pharmaceutical company Sartorius was able to present good business figures for the first quarter of 2022.

Sartorius is providing 1.3 million euros for a biotope project near Kiessee.